ZIOPHARM Oncology Inc.  

(Public, NASDAQ:ZIOP)   Watch this stock  
Find more results for ZIOP
4.86
+0.04 (0.83%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.69 - 4.92
52 week 4.45 - 14.93
Open 4.83
Vol / Avg. 1.34M/2.67M
Mkt cap 615.22M
P/E     -
Div/yield     -
EPS -0.42
Shares 131.84M
Beta 1.61
Inst. own 46%
Aug 8, 2016
Q2 2016 ZIOPHARM Oncology Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 12, 2016
ZIOPHARM Oncology Inc at Cantor Fitzgerald Healthcare Conference
Jun 9, 2016
ZIOPHARM Oncology Inc at Jefferies Healthcare Conference
May 10, 2016
Q1 2016 ZIOPHARM Oncology Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -610.41% -2772.11%
Operating margin -611.48% -2772.39%
EBITD margin - -2764.15%
Return on average assets -32.64% -120.72%
Return on average equity -58.37% -198.15%
Employees 28 -
CDP Score - -

Address

One First Avenue Parris Building 34 Navy Yard Plaza
BOSTON, MA 02129
United States - Map
+1-646-2140700 (Phone)
+1-617-2412855 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex. The Company's Ad-RTS-IL-12 + veledimex has been evaluated in two Phase II studies, the first for the treatment of metastatic melanoma, and the second for the treatment of unresectable recurrent or metastatic breast cancer. It has initiated the Phase I study for malignant glioma. The Company has completed the Phase II monotherapy studies in melanoma and breast cancer using Ad-RTS-IL-12 + veledimex. It has initiated a Phase Ib/II study of Ad-RTS-hIL-12 + veledimex following chemotherapy for the treatment of patients with locally metastatic breast cancer. Its initial drug candidate being developed using the synthetic immuno-oncology platform is Ad-RTS-IL-12 + veledimex.

Officers and directors

Laurence James Neil Cooper M.D., Ph.D. Chief Executive Officer
Age: 50
Bio & Compensation  - Reuters
Kevin G. Lafond CPA Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Treasurer
Age: 58
Bio & Compensation  - Reuters
Caesar J. Belbel Chief Operating Officer, Executive Vice President, Chief Legal Officer, Secretary
Age: 55
Bio & Compensation  - Reuters
Murray Brennan Non-Executive Lead Independent Director
Age: 75
Bio & Compensation  - Reuters
Randal J. Kirk Director
Age: 61
Bio & Compensation  - Reuters
James A. Cannon Independent Director
Age: 76
Bio & Compensation  - Reuters
Wyche Fowler Jr., J.D Independent Director
Age: 75
Bio & Compensation  - Reuters
Timothy McInerney Independent Director
Age: 54
Bio & Compensation  - Reuters